Initiator Pharma receives CTA approval for Phase 2b study with IPED2015 in Erectile Dysfunction patients
Initiator Pharma A/S, a clinical-stage life science company, announced today that it has received final approvals for the Clinical Trial Application (CTA) for its planned Phase 2b study in Erectile Dysfunction patients with IPED2015 from both the Medicines & Healthcare products Regulatory Agency, MHRA, UK and the Ethics Committee. The patient recruitment is expected to start at end of July. The study will be carried out in collaboration with MAC Clinical Research, UK, at multiple centers across UK.“IPED2015 is our most advanced ED candidate with potential to become a new treatment method